VRAX Virax Biolabs Group Ltd IFRS Annual reports only
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1885827 · Fiscal year ends 03/31
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-96.0%
TTM net income YoY10.0%
TTM EPS YoY51.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-838.2%
Operating margin-97,344.8%
Net margin-95,739.2%
FCF margin-81,621.6%
EBITDA margin-93,133.7%
Returns
ROE-109.6%
ROA-101.8%
ROIC (approx.)-300.1%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets15.0%
Debt / equity0.00x
Current ratio7.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-25.1%
Payout ratio—
Capex / revenue9,538.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 | FY20212021-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $6,331 | $156,419 | $8,561 | $0 | $123,820 |
| Cost of revenue | $59,398 | $105,829 | $9,926 | — | $133,254 |
| Gross profit | -$53,067 | $50,590 | -$1,365 | — | -$9,434 |
| R&D expense | $1.78M | $1.56M | $2.18M | $433,743 | $120,221 |
| SG&A expense | $4.33M | $4.59M | $3.55M | $1.30M | $457,680 |
| Operating income | -$6.16M | -$6.50M | -$5.73M | -$1.73M | -$644,538 |
| Pretax income | -$6.20M | -$6.74M | -$5.46M | -$1.75M | -$672,915 |
| Income tax | -$136,661 | — | — | — | — |
| Net income | -$6.06M | -$6.73M | -$5.46M | -$1.71M | -$650,984 |
| EBITDA | -$5.90M | -$6.44M | — | — | — |
| EPS (basic) | -1.62 | -3.36 | -5.13 | -1.79 | — |
| EPS (diluted) | -1.62 | -3.36 | -5.13 | -1.79 | — |
| Weighted avg. shares (diluted) | 3.73M | 2.01M | 1.06M | 956,326 | 1.58M |
| Banking | |||||
| Net interest income | $58,179 | -$26,878 | -$15,468 | -$15,438 | -$28,643 |
| Balance sheet | |||||
| Cash & equivalents | $4.23M | $3.59M | $9.35M | $21,756 | $17,621 |
| Receivables | — | — | — | — | $928 |
| Inventory | $94,675 | $60,383 | $0 | $20,951 | $21,072 |
| Current assets | $4.89M | $4.38M | $9.63M | $48,706 | $39,621 |
| PP&E, netmay include right-of-use assets (IFRS) | $1.23M | $897,627 | — | — | — |
| Intangibles | — | — | $178,403 | — | — |
| Total assets | $6.43M | $5.48M | $9.81M | $48,706 | $39,621 |
| Current liabilities | $673,207 | $168,849 | $908,401 | $1.25M | $871,435 |
| Total liabilities | $964,750 | $345,194 | $908,401 | $1.25M | $871,435 |
| Shareholders' equity | $5.70M | $5.37M | $9.13M | -$974,578 | -$650,682 |
| Shares outstanding | 4.34M | 2.57M | 1.55M | 9.98M | — |
| Cash flow statement | |||||
| Operating cash flow | -$4.56M | -$6.25M | -$4.18M | -$809,070 | -$590,186 |
| Capital expenditure | $603,890 | $952,497 | — | — | — |
| Free cash flow | -$5.17M | -$7.20M | — | — | — |
| Investing cash flow | -$603,890 | -$1.16M | -$178,403 | — | — |
| Financing cash flow | $5.81M | $1.65M | $13.69M | $813,205 | $585,198 |
| Depreciation & amortization | $266,601 | $54,870 | — | — | — |
| Stock-based compensation | $365,309 | $1.01M | $1.73M | $290,364 | — |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.